AbbVie share price logo

AbbVie

NYSE: ABBV

Mega Cap

$289.60

+6.92

(+2.45%)

Live

as on

AbbVie Stock Performance

as on October 21, 2026 at 5:17 am IST

  • Day's Low

    Day's High

    $285.78
    $290.98
    downward going graph

    1.32%

    Downside

    0.48%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $190.75
    $291.40
    downward going graph

    34.13%

    Downside

    0.62%

    Upside

    downward going graph

AbbVie share price movements today

Previous Close
$282.68
Open
$286.95
Volume
1.7M
Market Cap
$504.4B
Dividend Yield
2.42%
Day's Low - High
$285.78 - $290.98
52 Week Low - High
$190.75 - $291.40

AbbVie Historical Returns

1 Month Return
+ 7.09 %
3 Month Return
+ 11.56 %
1 Year Return
+ 21.81 %
3 Year Return
+ 93.31 %
5 Year Return
+ 160.75 %

AbbVie Stock Fundamentals & Key Indicators

Check AbbVie market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$504.4B

EPS (TTM)

3.5495

Dividend Yield

2.42%

Quarterly Earnings Growth YOY

2.90%

PE Ratio (TTM)

80.41

Industry PE ratio

28.28

PEG Ratio

1.18

EBITDA

21.2B

Revenue (TTM)

64.4B

Profit Margin

71.48%

Return On Equity TTM

-136.50%

AbbVie vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of AbbVie with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
AbbVie image
AbbVie
StrongBuy$504.4B160.75%80.4171.48%2.42%
Eli Lilly & Co image
Eli Lilly & Co
StrongBuy$1.2T408.92%42.0683.40%0.53%
Johnson & Johnson image
Johnson & Johnson
Buy$615.9B54.96%38.7568.81%2.07%
Merck & Company image
Merck & Company
Buy$360.1B77.17%115.8575.38%2.33%
AstraZeneca image
AstraZeneca
Buy$257.3B35.21%24.7279.27%1.95%

Stock Returns calculator for AbbVie Stock including INR - Dollar returns

The AbbVie stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

AbbVie investment value today

Current value as on today

₹1,34,814

Returns

₹34,814

(+34.81%)

Returns from AbbVie Stock

₹24,795 (+24.8%)

Dollar Impact

₹10,019 (+10.02%)

Analyst Recommendation on AbbVie Stock

Based on 19 analysts

BUY

84.21%

Buy

15.79%

Hold

0.00%

Sell

Based on 19 analysts, 84.21052631578947% of analysts recommend a 'BUY' rating for AbbVie. Average target price of $282.61

AbbVie Share Price Target

Get share price movements and forecasts by analysts on AbbVie.

What analysts predicted

-2.47%DOWNSIDE

Target Price

$282.61

Current Price

$289.6

Analyzed by

19 Analysts

High

$320

Target

$282.61

Low

$225

AbbVie target price $282.61, a slight downside of -2.47% compared to current price of $289.6. According to 19 analysts rating.

Indian Investors' Interest in AbbVie Stock

Investment in AbbVie Shares on INDmoney has grown by 94.07% in the last 30 days, indicating increased investment activity.

Time period: to

Change:94.07% versus previous 30 day period

Search interest for AbbVie Stock has increased by 61% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:61% versus previous 30 day period

AbbVie Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
12,310
14,462
14,460
15,102
13,343
15,423
15,776
16,618
15,002
16,990
Gross Profit
8,216
10,260
10,248
10,706
9,341
11,077
10,472
12,066
10,784
12,699
Operating Income
2,798
3,998
3,831
-1,490
3,733
4,894
1,904
5,809
4,734
6,432
EBITDA
4,489
5,003
4,883
535
4,400
4,344
3,516
5,369
3,692
8,606
Interest Expense
660
726
720
702
700
740
739
714
717
746
Depreciation
2,074
2,131
2,079
2,102
2,039
2,050
2,063
1,987
1,936
1,883
Income Before Tax
1,755
2,146
2,084
-2,269
1,661
1,554
714
2,668
1,039
4,278
Income Tax Expense
383
773
520
-2,246
372
613
526
853
342
662
Net Income
1,369
1,370
1,561
-22
1,286
938
186
1,816
699
3,613
Net Profit Margin
66.74%
70.94%
70.87%
70.89%
70.01%
71.82%
66.38%
72.61%
71.88%
74.74%

AbbVie Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
Gross Profit
21,176
25,035
25,827
30,417
38,751
40,640
33,903
39,430
42,956
Operating Income
9,545
6,383
12,983
11,363
17,924
18,117
12,757
9,137
20,091
EBITDA
10,378
8,310
12,227
12,323
23,933
24,174
17,172
14,910
17,629
Interest Expense
1,150
1,348
1,784
2,454
2,423
2,230
2,224
2,808
2,893
Depreciation
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
Income Before Tax
7,727
5,197
8,426
3,398
12,989
13,477
6,250
3,716
6,597
Income Tax Expense
2,418
-490
544
-1,224
1,440
1,632
1,377
-570
2,364
Net Income
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
Net Profit Margin
75.05%
76.44%
77.64%
66.41%
68.96%
70.00%
62.42%
69.99%
70.24%

AbbVie Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
1,359
1,373
1,590
-23
1,289
941
188
1,816
697
3,616
Operating Cash Flow
4,040
2,271
5,447
7,048
1,635
5,153
7,024
5,218
3,829
3,436
Investing Cash Flow
-9,588
-1,102
-8,256
-1,874
-735
-1,181
-3,264
-1,463
-574
-1,197
Financing Cash Flow
10,819
-6,097
-3,072
-6,861
-1,258
-2,710
-4,590
-4,166
919
-5,054
Change in Cash
5,253
-4,937
-5,873
-1,733
-349
1,292
-838
-400
4,162
-2,822

AbbVie Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
5,309
5,687
7,882
4,622
11,549
11,845
4,820
4,286
4,226
Operating Cash Flow
9,960
13,427
13,324
17,588
22,777
24,943
22,839
18,806
19,030
Investing Cash Flow
-274
-1,006
596
-37,557
-2,344
-623
-2,009
-20,820
-6,643
Financing Cash Flow
-5,512
-14,396
18,708
-11,501
-19,039
-24,803
-17,222
-5,211
-12,724
Change in Cash
4,203
-2,014
32,635
-31,475
1,297
-545
3,613
-7,290
-295

Global Institutional Holdings in AbbVie

Check out the Institutions with significant holdings in AbbVie.

Funds
Holdings
Vanguard
9.04%
VANGUARD INDEX FUNDS
6.76%
iShares
4.85%
SPDR
4.14%
Fidelity Concord Street Trust
1.70%
See all

AbbVie News & Key Events

  • img

    Today's Timeline - 19 October

    Mon, 01:30 PM

    -

    AbbVie presents data for ABBV-466, demonstrating higher endoscopic remission rates than anti-IL-23 or anti-α4β7 monotherapy.

    Mon, 02:40 PM

    -

    AbbVie reports ABBV-466 trial meets primary endpoint, showing higher endoscopic remission rates in Crohn's disease than monotherapy.

    Mon, 05:30 PM

    -

    Neuroscience segment shows growth potential; investors await Q3 results on October 30.

  • img

    Today's Timeline - 19 October

    Mon, 07:13 PM

    -

    AbbVie reports Q2 revenue growth of 10.2%, driven by Skyrizi and Rinvoq, indicating successful post-Humira strategy.

    Mon, 08:45 PM

    -

    AbbVie unveils Phase 2a Crohn's data and plans for 2026 ESMO readouts, indicating strong pipeline execution.

Insights on AbbVie

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    AbbVie Inc. has shown strong profit growth over the last two quarters. In the most recent quarter, the company's net profit increased significantly from $699 million to $3.61 billion. This represents an average growth rate of 80.7% per quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    AbbVie Inc. has shown positive revenue growth over the last two quarters. In the most recent quarter, the revenue increased from $15.00 billion to $16.99 billion, reflecting an average growth rate of 11.7% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, ABBV stock has moved up by 38.8%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ABBV has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 66.4% return, outperforming this stock by 44.6%

About AbbVie

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
OrganisationAbbVie
Headquarters1 North Waukegan Road, North Chicago, IL, 60064-6400, US
IndustryDrug Manufacturers - General
CEORobert A. Michael

Key Management of AbbVie

Name

Title

Mr. Jeffrey Ryan Stewart

Executive VP & Chief Commercial Officer

Mr. Perry C. Siatis

Executive VP, General Counsel & Secretary

Mr. Scott T. Reents

Executive VP & CFO

Dr. Azita Saleki Ph.D.

Executive VP & COO

Ms. Linda Ray

Senior VP & Chief Information Officer

Ms. Elizabeth Shea

Senior Vice President of Investor Relations

Mr. Demetris D. Crum

Executive VP & Chief Human Resources Officer

Mr. Wulff-Erik von Borcke

Senior VP & President of Oncology

Mr. Robert A. Michael CPA

CEO & Chairman of the Board

Dr. Roopal B. Thakkar M.D.

Executive VP of Research & Development and Chief Scientific Officer

FAQs

What is AbbVie share price today?

AbbVie share price today is $289.60 as on . AbbVie share today touched a day high of $290.98 and a low of $285.78.

What is the 52 week high and 52 week low for AbbVie share?

AbbVie share touched a 52 week high of $291.40 on and a 52 week low of $190.75 on . AbbVie stock price today i.e. is trending at $289.60,which is 0.62% down from its 52 week high and 51.82% up from its 52 week low.

What is AbbVie's market capitalisation today?

AbbVie market capitalisation is $0.50T as on .

How to invest in AbbVie Stock (ABBV) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for AbbVie on INDmoney app. Click on Buy button.

What is the minimum amount required to buy AbbVie Stock (ABBV) from India?

Indian investors can start investing in AbbVie (ABBV) shares with as little as ₹94.93000030517578 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.30 in AbbVie stock (as per the Rupee-Dollar exchange rate as on ). Based on AbbVie share’s latest price of $289.60 as on October 20, 2026 at 11:47 pm IST, you will get 0.0345 shares of AbbVie. Learn more about fractional shares .

What are the returns that AbbVie has given to Indian investors in the last 5 years?

AbbVie stock has given 160.75% share price returns and 26.42% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?